Future Directions in Sepsis Immunotherapy: From Bench to Bedside

Dr Neeraj Manikath , claude.ai

Abstract

Sepsis remains a leading cause of morbidity and mortality worldwide, with immune dysregulation playing a central role in its pathophysiology. Despite advances in supportive care, mortality rates remain unacceptably high, particularly in septic shock. The failure of numerous anti-inflammatory trials has prompted a paradigm shift toward understanding sepsis as a syndrome of simultaneous hyperinflammation and immunosuppression. This review examines emerging immunotherapeutic strategies, including immune checkpoint inhibitors, cytokine modulation, metabolic reprogramming, extracorporeal immunomodulation, and precision medicine approaches. We explore the translational challenges and highlight promising avenues that may transform sepsis management in the coming decade.

Introduction

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, affects approximately 49 million people annually and accounts for 11 million deaths worldwide.¹ The Sepsis-3 definitions emphasize organ dysfunction rather than inflammation alone, reflecting our evolving understanding of this complex syndrome.² Despite decades of research and over 100 failed clinical trials, supportive care with antibiotics, fluids, and vasopressors remains the cornerstone of management.³

The immunological landscape of sepsis is heterogeneous and dynamic, characterized by an initial hyperinflammatory phase followed by a prolonged immunosuppressive phase in many patients.⁴ This biphasic response explains why anti-inflammatory strategies have largely failed and underscores the need for personalized, time-sensitive immunomodulation.

Pearl: Sepsis is not simply "too much inflammation"—it's immune chaos. Patients can simultaneously exhibit features of hyperinflammation in some compartments and immunoparalysis in others, demanding precision rather than blanket immunosuppression.

The Immunological Paradigm Shift

From Anti-Inflammation to Immunomodulation

The failure of anti-TNF, anti-IL-1, and corticosteroid trials (with few exceptions) taught us that global immunosuppression is not the answer.⁵ Modern sepsis immunology recognizes:

Temporal heterogeneity: Early hyperinflammation transitions to late immunosuppression
Spatial heterogeneity: Concurrent inflammation and immune exhaustion in different compartments
Patient heterogeneity: Genetic, comorbid, and pathogen-specific factors create diverse phenotypes

Immune Endotypes in Sepsis

Recent transcriptomic studies have identified distinct sepsis response signatures (SRS):⁶

SRS1: Immunosuppressed phenotype with high mortality
SRS2: Hyperinflammatory phenotype with intermediate mortality
SRS3: Adaptive immune activation with better outcomes

Hack: Think of sepsis endotypes like heart failure phenotypes (HFrEF vs HFpEF)—different biology, different targets, different therapies. One size does NOT fit all.

Immune Checkpoint Inhibitors: Reversing Immunoparalysis

The Rationale

Prolonged sepsis induces T-cell exhaustion characterized by upregulation of inhibitory receptors (PD-1, PD-L1, CTLA-4, TIM-3, LAG-3) and functional impairment.⁷ This immunoparalysis predisposes to secondary infections and contributes to late mortality.

Post-mortem studies reveal profound lymphocyte apoptosis, particularly affecting CD4+ T cells and B cells.⁸ Survivors often exhibit persistent immune dysfunction resembling accelerated immunosenescence.

Clinical Evidence

Anti-PD-1/PD-L1 Therapy:

Phase 1b trial of nivolumab (anti-PD-1) in septic patients showed restoration of monocyte HLA-DR expression and immune responsiveness⁹
The ongoing IRIS trial (NCT04990232) is evaluating anti-PD-L1 antibody in patients with persistent sepsis-induced immunosuppression
Preclinical data demonstrate improved bacterial clearance and survival in murine models¹⁰

Anti-CTLA-4 Therapy:

Showed promise in reversing lymphocyte apoptosis in experimental models
Not yet tested in human sepsis trials

Oyster: The oncology-sepsis paradox: Cancer patients receiving checkpoint inhibitors who develop sepsis may have better outcomes, potentially due to prevented immunosuppression.¹¹ This natural experiment supports the therapeutic hypothesis.

Patient Selection Challenges

Not all septic patients are immunosuppressed. Biomarker-guided selection is critical:

HLA-DR expression on monocytes (mHLA-DR) <8,000 molecules/cell indicates monosuppression¹²
Decreased TNF-α production upon ex vivo LPS stimulation
Lymphopenia (absolute lymphocyte count <1,000/μL) persisting beyond 72 hours
Elevated IL-10 with suppressed IFN-γ

Pearl: Measure, don't guess. Giving checkpoint inhibitors to hyperinflammatory patients could be catastrophic. Flow cytometry for HLA-DR should become standard in sepsis ICUs, just as lactate is today.

Cytokine Modulation: Precision Targeting

IL-7: The Lymphocyte Rescuer

Recombinant human IL-7 (rhIL-7) promotes T-cell proliferation and prevents apoptosis:

Phase 2 trial (IRIS-7) showed increased CD4+ and CD8+ T-cell counts with restoration of immune function¹³
Well-tolerated without cytokine storm
Potential to reduce secondary infections and late mortality

GM-CSF: Monocyte Activation

Granulocyte-macrophage colony-stimulating factor enhances neutrophil and monocyte function:

Increases HLA-DR expression on monocytes
Phase 2 trials showed immune restoration without adverse events¹⁴
May be particularly useful in patients with persistently low mHLA-DR

IFN-γ: Macrophage Priming

Interferon-gamma reactivates macrophages from M2 (immunosuppressive) toward M1 (antimicrobial) phenotype:

Small trials showed improved monocyte function and reduced infection rates¹⁵
Risk of excessive inflammation requires careful patient selection

Antagonizing Immunosuppressive Mediators

IL-10 neutralization and adenosine pathway inhibition represent novel targets to prevent the anti-inflammatory overshoot.¹⁶

Hack: The "immunostat" concept: Just as we titrate vasopressors to blood pressure, future sepsis care will titrate immunotherapy to functional immune assays—real-time adjustment based on ex vivo immune response testing.

Metabolic Reprogramming: Restoring Immune Cell Function

Mitochondrial Dysfunction in Sepsis

Septic immune cells exhibit metabolic exhaustion:

Impaired oxidative phosphorylation
Reduced ATP production
Accumulation of reactive oxygen species
Dysfunctional mitophagy¹⁷

Therapeutic Strategies

1. Metabolic Substrates:

Vitamin C: High-dose intravenous vitamin C may reduce oxidative stress and restore mitochondrial function (though controversial after LOVIT trial)¹⁸
Thiamine: Corrects pyruvate dehydrogenase dysfunction, particularly in thiamine-deficient patients
Selenium: Antioxidant with mixed trial results

2. NAD+ Enhancement:

Nicotinamide riboside and NMN precursors restore cellular energy metabolism¹⁹
Preclinical promise, early human trials underway

3. Mitochondrial Transplantation:

Experimental delivery of healthy mitochondria to restore cellular bioenergetics²⁰
Proof-of-concept in cardiac arrest; potential applicability to septic shock

Pearl: Septic immune cells are like cars running out of gas—they may have the right receptors and signaling machinery, but without metabolic fuel, they can't function. Fixing metabolism may be as important as modulating cytokines.

Extracorporeal Immunomodulation

Hemoadsorption Devices

CytoSorb:

Polymer bead cartridge removes cytokines by adsorption
Mixed results in RCTs; may benefit hyperinflammatory phenotypes²¹
Ongoing trials examining timing and patient selection

Seraph 100 Microbind Affinity:

Removes pathogens and endotoxin directly from blood
Early data suggest reduced vasopressor requirements²²

Extracorporeal Blood Purification

High-volume hemofiltration and coupled plasma filtration-adsorption aim to remove inflammatory mediators, though evidence remains inconclusive.²³

Oyster: The "Goldilocks problem": Removing too many cytokines may impair pathogen clearance; removing too few has no effect. Success may depend on identifying the hyperinflammatory phenotype and applying therapy in the first 24-48 hours.

Precision Medicine and Biomarker-Driven Therapy

Theranostic Approaches

The future of sepsis immunotherapy is precision-based:

1. Rapid Endotyping:

Point-of-care transcriptomic panels (e.g., SeptiCyte RAPID)²⁴
Functional immune assays (neutrophil function, monocyte HLA-DR)
Metabolomic profiling

2. Dynamic Monitoring:

Serial immune measurements to guide therapy escalation/de-escalation
Integration with electronic medical records for real-time decision support

3. Combination Strategies:

Sequential therapy: anti-inflammatory in hyperinflammatory phase → immune stimulation in immunosuppressive phase
Synergistic combinations: e.g., IL-7 + anti-PD-1 for profound immunoparalysis

Hack: Build your "sepsis immune panel" like a cardiac panel: Lactate + mHLA-DR + absolute lymphocyte count + IL-6. Track trends, not just single values. Rising mHLA-DR is success; persistent suppression demands intervention.

Emerging and Novel Strategies

1. Trained Immunity Modulation

β-glucans and other PAMPs induce epigenetic reprogramming of innate cells
May prevent immunosuppression if administered early²⁵

2. Regulatory T Cell Depletion

Anti-CD25 antibodies selectively reduce Tregs that suppress immune responses
Preclinical models show improved bacterial clearance²⁶

3. Mesenchymal Stem Cells (MSCs)

Immunomodulatory and regenerative properties
Phase 2 trials show safety; efficacy data pending²⁷
May be beneficial in ARDS and multi-organ dysfunction

4. CAR-T and CAR-M Cells

Chimeric antigen receptor technology adapted for sepsis
CAR-M (CAR-macrophages) engineered to target specific pathogens or DAMPs²⁸
Highly experimental but conceptually revolutionary

5. Microbiome Modulation

Sepsis disrupts gut microbiota, promoting pathobiont expansion
Fecal microbiota transplantation and selective probiotics under investigation²⁹

Pearl: The microbiome is the "forgotten organ" in critical care. Gut dysbiosis in sepsis isn't just a consequence—it's a perpetuator of immune dysfunction and a therapeutic target.

Challenges and Future Directions

Translational Barriers

Heterogeneity: Patient variability demands adaptive trial designs (basket trials, platform trials)
Timing: The therapeutic window may be narrow and patient-specific
Endpoints: Short-term mortality may miss benefits in long-term immune recovery
Regulatory: Approval pathways for combination immunotherapy are unclear

The Path Forward

1. Biomarker Qualification:

Validate immune functional assays as surrogate endpoints
Regulatory acceptance of endotype-specific indications

2. Adaptive Platform Trials:

REMAP-CAP model for testing multiple interventions
Enrichment strategies for likely responders

3. Artificial Intelligence:

Machine learning to predict endotypes from EHR data
Clinical decision support for immunotherapy selection³⁰

4. Long-Term Outcomes:

Focus on sepsis survivorship, chronic critical illness, and quality of life
Immune restoration as a goal beyond 28-day mortality

Oyster: The future ICU will have an "immunotherapy pharmacist" just like we have antimicrobial stewards—someone monitoring immune function daily and adjusting therapy accordingly.

Clinical Implementation Framework

For the practicing intensivist preparing for the immunotherapy era:

Now (2025-2027):

Implement routine HLA-DR monitoring where available
Participate in immunotherapy trials
Phenotype patients even if no specific therapy is available (build experience)

Near-term (2027-2030):

Expect first approved immunostimulatory agents (likely IL-7 or anti-PD-1)
Develop institutional protocols for immune monitoring
Train multidisciplinary teams in immunotherapy management

Long-term (2030+):

Personalized sepsis immunotherapy as standard of care
Point-of-care immune function testing
Combination organ support and immunomodulation devices

Hack: Start building your sepsis phenotyping database now. When immunotherapies arrive, centers with existing experience in immune monitoring will be first adopters and will generate the real-world evidence.

Conclusion

Sepsis immunotherapy stands at an inflection point. The failures of the past have illuminated the path forward: precision rather than protocols, immunomodulation rather than immunosuppression, and dynamic adjustment rather than static interventions. The convergence of advanced diagnostics, computational biology, and targeted biologics promises to transform sepsis from a syndrome we support to a disease we treat.

The next decade will likely see the first immunotherapies integrated into routine sepsis care, initially for selected phenotypes and eventually expanding as our diagnostic capabilities mature. Success will require collaboration across disciplines—immunologists, intensivists, industry, and regulators—and a willingness to fundamentally rethink sepsis management.

Final Pearl: We are not waiting for a single "magic bullet" for sepsis—we're building an armamentarium of precision weapons. The question is not IF sepsis immunotherapy will work, but WHEN we'll be skilled enough to deploy the right therapy to the right patient at the right time.

Key Takeaways for Clinical Practice

Sepsis is immunologically heterogeneous; treat phenotypes, not syndromes
Monitor immune function (especially HLA-DR) to identify immunosuppressed patients
Consider immune restoration therapy in patients with persistent lymphopenia and low HLA-DR
Time matters: hyperinflammation may need dampening, but immunoparalysis needs stimulation
Combine immunotherapy with optimal supportive care, source control, and antimicrobials
Long-term outcomes and immune recovery should be therapeutic goals

References

Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195-203.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851.
Sweeney TE, Azad TD, Donato M, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018;46(6):915-925.
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-2605.
Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952-6963.
Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47(5):632-642.
Shindo Y, McDonough JS, Chang KC, et al. Anti-PD-L1 peptide improves survival in sepsis. J Surg Res. 2017;208:33-39.
Lemiale V, Meert AP, Vincent F, et al. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Ann Intensive Care. 2019;9(1):25.
Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32(8):1175-1183.
Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3(5):e98960.
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-648.
Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678-681.
Cavaillon JM, Eisen DP, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care. 2020;24(1):477.
Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72.
Lamontagne F, Masse MH, Menard J, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022;386(25):2387-2398.
Cant R, Dalgleish AG, Allen RL. NAD+ depletion in aged macrophages is a targetable checkpoint for cancer immunotherapy. Cancer Immunol Res. 2021;9(1):83-95.
McCully JD, Cowan DB, Pacak CA, et al. Injection of isolated mitochondria during early reperfusion for cardioprotection. Am J Physiol Heart Circ Physiol. 2009;296(1):H94-H105.
Hawchar F, László I, Öveges N, et al. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172-178.
Olson SW, Oliver JD, Collen J, et al. Treatment of Staphylococcus aureus bacteremia with the Seraph® 100 microbind affinity blood filter. J Extra Corpor Technol. 2021;53(4):278-283.
Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205.
Miller RR 3rd, Lopansri BK, Burke JP, et al. Validation of a host response assay, SeptiCyte LAB, for discriminating sepsis from systemic inflammatory response syndrome in the ICU. Am J Respir Crit Care Med. 2018;198(7):903-913.
Novakovic B, Habibi E, Wang SY, et al. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell. 2016;167(5):1354-1368.e14.
Nascimento DC, Melo PH, Piñeros AR, et al. IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat Commun. 2017;8:14919.
McIntyre LA, Stewart DJ, Mei SHJ, et al. Cellular immunotherapy for septic shock: a phase I clinical trial. Am J Respir Crit Care Med. 2018;197(3):337-347.
Zhang F, Parayath NN, Ene CI, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974.
Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin. 2016;32(2):203-212.
Gutierrez G. Artificial intelligence in the intensive care unit. Crit Care. 2020;24(1):101.

Abbreviations

ARDS - Acute Respiratory Distress Syndrome
ATP - Adenosine Triphosphate
CAR - Chimeric Antigen Receptor
CTLA-4 - Cytotoxic T-Lymphocyte-Associated Protein 4
DAMP - Damage-Associated Molecular Pattern
EHR - Electronic Health Record
GM-CSF - Granulocyte-Macrophage Colony-Stimulating Factor
HLA-DR - Human Leukocyte Antigen-DR
ICU - Intensive Care Unit
IFN-γ - Interferon-gamma
IL - Interleukin
LAG-3 - Lymphocyte-Activation Gene 3
LPS - Lipopolysaccharide
mHLA-DR - Monocytic HLA-DR
MSC - Mesenchymal Stem Cell
NAD+ - Nicotinamide Adenine Dinucleotide
NMN - Nicotinamide Mononucleotide
PAMP - Pathogen-Associated Molecular Pattern
PD-1 - Programmed Cell Death Protein 1
PD-L1 - Programmed Death-Ligand 1
RCT - Randomized Controlled Trial
SRS - Sepsis Response Signature
TIM-3 - T-cell Immunoglobulin and Mucin-domain containing-3
TNF-α - Tumor Necrosis Factor-alpha
Treg - Regulatory T Cell

This review provides a comprehensive overview of current and emerging immunotherapeutic strategies in sepsis management. The field is rapidly evolving, and clinicians should stay abreast of ongoing clinical trials and evolving evidence.

Sunday, November 2, 2025